• Neuronetics

  Participated · Series G · Jun 2017

  Neuronetics develops non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. The company is considered a leader in transcranial magnetic stimulation (TMS) and has developed NeuroStar® Advanced Therapy, a noninvasive neuromodulation treatment for adult patients with Major Depressive Disorder (MDD). NeuroStar Advanced Therapy has delivered 1.4 million treatments to more than 50,000 patients. Led by President and CEO Chris Thatcher, Neuronetics is based in Malvern, Pa. The company closed a $15M Series G equity round and intends to use the funds to continue to expand operations. The funding supports its commercial and operational growth around its NeuroStar therapy. Neuronetics develops non-invasive transcranial magnetic stimulation (TMS) therapies centered on its NeuroStar TMS Therapy System. The NeuroStar system is indicated for treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. It is a non-systemic, non-invasive neuromodulation therapy that stimulates nerve cells by delivering highly focused MRI-strength magnetic field pulses, activating cortical and deep brain structures involved in mood regulation. Treatments are prescription-only and are typically administered daily for 4–6 weeks. The company completed a $34M Series F financing and plans to use the proceeds to expand its commercial resources. Neuronetics also intends to fund a new registration study to investigate NeuroStar TMS Therapy for Major Depressive Disorder in adolescents aged 12 to 21. Neuronetics develops the NeuroStar transcranial magnetic stimulation (TMS) system for the treatment of major depression. The NeuroStar system was cleared by the U.S. FDA in October 2008 and delivers focused MRI‑strength magnetic field pulses to stimulate nerve cells in a brain region linked to depression. The therapy is non‑invasive, does not circulate in the bloodstream or involve surgery, and is typically administered daily for four to six weeks. The treatment is available at more than 300 treatment centers in the United States. Neuronetics completed a $30M Series E financing to expand the reach of NeuroStar for patients who did not get relief from existing therapies. The company is led by President and CEO Bruce J. Shook.

• Nevro

  Participated · Series C · Mar 2013

  Nevro Corp., headquartered in Menlo Park, California, develops and commercializes high-frequency spinal cord stimulation (HF-SCS) for the treatment of chronic pain and other disorders. Its flagship product is the Senza HF-SCS system, the only SCS system capable of delivering HF10 therapy up to 10 kHz. The company says its proprietary high-frequency technology appears unique in its potential to treat challenging conditions such as low back pain while enhancing patient experience. The Senza system is authorized for sale and commercially available in Europe and Australia, while in the United States it is limited to investigational use. Nevro has initiated a substantial U.S. pivotal study, built a growing intellectual property portfolio, and demonstrated commercial traction at leading international pain centers. The company plans to complete the pivotal study, seek U.S. regulatory approval, invest in clinical evidence for new indications, and support international and U.S. commercialization. Nevro develops neuromodulation technology for chronic pain relief, including the Nevro Spinal Cord Stimulation System. The company’s Spinal Cord Stimulation System received CE mark in 2010 and is commercially available at leading centers outside the United States. Nevro is privately held and was founded in 2007, headquartered in Menlo Park, California. The company plans to sponsor a pivotal clinical study in the U.S. to support regulatory and clinical development. Management also intends to use new funds to continue its international commercialization strategy and expand into global markets. Current financial activity includes a newly completed $58 million financing to support these development and commercialization efforts.

• NOVASYS MEDICAL

  Participated · Equity · Sep 2012

  Novasys Medical's core product, the Renessa System, uses a probe guided through the urethra and radiofrequency energy to treat female stress urinary incontinence as an alternative to surgical treatments. The Renessa System has been cleared by the U.S. Food and Drug Administration. The company competes with other noninvasive and minimally invasive options, such as Uroplasty's Urgent PC, Boston Scientific's urethral bulking agents, and Medtronic's implantable InterStim. The National Association for Continence estimates that 75–80% of the 25 million Americans who suffer stress urinary incontinence are women, indicating a large addressable market. Management listed in the article includes Scott Cramer (president and CEO), Michael Gandy (CFO), and Damian P. Alagia III (medical director and VP of Medical Affairs). The company reported a $3.9 million raise in a regulatory filing, but the article notes the company did not disclose how proceeds will be used and a spokeswoman did not return a call. Novasys Medical makes a medical device intended to treat female stress urinary incontinence. The company’s product is described by its CEO as the only real alternative to surgery for women with the condition. Novasys is based in Newark, Calif. The company recently completed a $49.5 million funding round. The financing was reported in VentureWire alongside a CEO interview about the device. Investors in the round span multiple venture firms and institutional backers.

• Inova Labs

  Participated · Series B · Nov 2011

  Inova Labs is an Austin medical device company focused on the Chronic Obstructive Pulmonary Disease (COPD) market. Its core product is the FDA-approved LifeChoice® Portable Oxygen Concentrator System, which uses proprietary “Pulse Wave” technology and an “Auto Mode” to deliver prescribed oxygen during activity and sleep. The device is FAA-approved for air travel and is manufactured under strict ISO certification guidelines. Led by CEO John Rush, the company is commercializing LifeChoice and plans to bring additional devices to market. Inova Labs secured up to $17.5M in Series B equity financing to support its commercial launch and product expansion. Inova Labs develops, manufactures and supplies medical devices, notably the LifeChoice® portable oxygen concentrator product line. The LifeChoice line is manufactured in Austin, Texas. The company plans nationwide and international sales expansion and continuation of next-stage product developments. Proceeds from the recent financing will also support working capital. Management expects to hire about 75 additional sales, marketing, engineering and manufacturing-related employees over the next year. Dr. Richard Lin of Three Arch Partners will join Inova’s board in conjunction with the funding.

• Tibion Bionic Technologies

  Led · Equity · Mar 2011

  Tibion Corporation develops the Bionic Leg, a wearable gait-rehabilitation robot intended to assist stroke survivors with sit-to-stand, overground walking and stair-climbing exercises. Therapists using the Bionic Leg report clinical benefits often from the first session, and the company began marketing the device in January 2010. Tibion says its device provides the assistance and resistance required by a stroke survivor’s weakened leg to promote the “brain re-wiring” believed necessary for gait recovery. Customers span the U.S., including inpatient rehabilitation facilities, skilled nursing facilities and free-standing physical therapy clinics, and some customers have ordered second and third units. The company reported a surge in placements at the end of 2010 and plans to accelerate roll-out of a new interchangeable battery version of the wearable robot, expand sales and marketing, and ramp up production and support. Tibion is privately held and announced a $10.175 million financing round to support these expansion plans.

No current team members are available.